

Phase III ESRD Clinical Performance Measures in effect April 1, 2008

Anemia Management	Measure Description
Assessment of Iron Stores - Facility Level	Percentage of all adult (≥ 18 years old) hemodialysis or peritoneal dialysis patients prescribed an ESA at any time during the reporting period or who have a Hemoglobin < 11.0 g/dL in at least one month of the reporting period for whom serum ferritin concentration AND either percent transferrin saturation or reticulocyte Hemoglobin content (CHr) are measured at least once in a three-month period for in-center hemodialysis patients, and at least twice during a six-month period for peritoneal dialysis patients and home hemodialysis patients.
Hemoglobin control for ESA therapy - Facility Level	Adult hemodialysis and peritoneal dialysis patients, with ESRD ≥ 3 months, who have received ESA therapy at any time during a 3 month reporting period AND have achieved a mean hemoglobin of 10.0-12.0 g/dL for the 3 month reporting period. The hemoglobin value reported for the end of each month (end-of-month Hemoglobin) is used for the calculation.
Monitoring hemoglobin levels below target minimum - Facility Level	Adult hemodialysis and peritoneal dialysis patients, with ESRD ≥ 3 months, who have a mean Hemoglobin < 10.0 g/dL for a 3 month reporting period, irrespective of ESA use. The hemoglobin value reported for the end of each reporting month (end-of-month Hemoglobin) is used for the calculation.
Hematocrit control for ESA therapy - Facility Level	Adult hemodialysis and peritoneal dialysis patients, with ESRD ≥ 3 months, who have received ESA therapy at any time during a 3 month reporting period AND have achieved a mean hematocrit of 30 – 36% for the 3 month reporting period. The hematocrit value reported for the end of each month (end-of-month Hematocrit) is used for the calculation.
Monitoring hematocrit levels below target minimum - Facility Level	Adult hemodialysis and peritoneal dialysis patients, with ESRD ≥ 3 months, who have a mean Hematocrit $< 30\%$ for a 3 month reporting period, irrespective of ESA use. The hematocrit value reported for the end of each month (end-of-month Hematocrit) is used for the calculation.

Phase III ESRD Clinical Performance Measures in effect April 1, 2008

Hemodialysis Adequacy	Measure Description
Hemodialysis Adequacy- Monthly measurement of delivered dose	Percentage of all adult (≥ 18 years old) HD patients in the sample for analyses with documented monthly adequacy measurements (spKt/V) or its components in the calendar month
Method of Measurement of Delivered Hemodialysis Dose	Percentage of all adult (>18 years old) in-center HD patients in the sample for analyses for whom delivered HD dose was calculated using UKM or Daugirdas II during the reporting period and for whom the frequency of HD per week is specified.
Minimum delivered hemodialysis dose for ESRD hemodialysis patients undergoing dialytic treatment for a period of 6 months or greater. – Facility Level	Percentage of all adult (≥ 18 years old) patients in the sample for analysis who have been on hemodialysis for 6 months or more and dialyzing thrice weekly whose delivered dose of hemodialysis (calculated from the last measurements of the month using the UKM or Daugirdas II formula) was a spKt/V ≥ 1.2 during the reporting period.
Minimum delivered hemodialysis dose for ESRD hemodialysis patients undergoing dialytic treatment for a period of 90 days or greater. – Facility Level	Percentage of all adult (≥ 18 years old) patients in the sample for analysis who have been on hemodialysis for 90 days or more and dialyzing thrice weekly, and have a residual renal function (if measured in the last three months) less than 2 ml/min/1.73m ²), whose delivered dose of hemodialysis (calculated from the last measurements of the month using the UKM or Daugirdas II formula) was a spKt/V ≥ 1.2 during the reporting period.
Percentage of the facility's hemodialysis patients with a urea reduction ratio (URR) of 65% or greater in the calendar year – Facility Level	Number of eligible Medicare hemodialysis patients at the facility during the calendar year with a median URR value of 65% or higher.
Peritoneal Dialysis Adequacy	Measure Description
Measurement of total Solute Clearance at regular intervals – Facility Level	Percentage of all adult (≥ 18 years old) peritoneal dialysis patients with total solute clearance for urea (endogenous residual renal urea clearance & dialytic) measured at least once in a four month time period.

Phase III ESRD Clinical Performance Measures in effect April 1, 2008

Delivered Dose of peritoneal dialysis above the minimum of 1.7 – Facility Level	Percentage of all adult (≥ 18 years old) peritoneal dialysis patients whose delivered peritoneal dialysis dose was a weekly Kt/Vurea of at least 1.7 (dialytic + residual) during the four month reporting period.
Mineral Metabolism	Measure Description
Measurement of Serum Calcium Concentration - Facility Level	Percentage of all adult (≥ 18 years of age) peritoneal dialysis and hemodialysis patients included in the sample for analysis with serum calcium measured at least once within month
Measurement of Serum Phosphorus Concentration – Facility Level	Percentage of all adult (≥ 18 years of age) peritoneal dialysis and hemodialysis patients included in the sample for analysis with serum phosphorus measured at least once within month.
Vascular Access	Measure Description
Minimizing use of catheters as Chronic Dialysis Access – Facility Level	Percentage of patients on maintenance hemodialysis during the last HD treatment of reporting period with a chronic catheter continuously for 90 days or longer prior to the last hemodialysis session
Maximizing Placement of Arterial Venous Fistula (AVF) - Facility Level	Percentage of patients on maintenance hemodialysis during the last HD treatment of month using an autogenous AV fistula with two needles
Functional Autogenous AV Fistula Access or referral to vascular surgeon for placement - Clinician Level	Percentage of all ESRD patients aged 18 years and older receiving hemodialysis during the 12 month reporting year who have a functional autogenous AV fistula (defined as two needles used) or do not have such a fistula but have been seen by a vascular surgeon for evaluation for permanent access at least once during the reporting year.
Catheter Vascular Access and referred to vascular for evaluation for a permanent access - Clinician Level	Percentage of all ESRD patients aged 18 years and older receiving hemodialysis during the 12 month reporting year with a catheter after 90 days on dialysis who are seen by a vascular surgeon for evaluation for permanent access at least once during the 12 month reporting period.
Decision-making by Surgeon to Maximize Placement of Autogenous Arterial Venous Fistula - Clinician Level	Percentage of patients with advanced chronic disease (CKD4 or 5) or end-stage renal disease (ESRD) undergoing open surgical implantation of permanent hemodialysis access who receive an autogenous arteriovenous fistula (AVF).

Phase III ESRD Clinical Performance Measures in effect April 1, 2008

Influenza Vaccination	Measure Description
Influenza Immunization – Clinician Level	Percentage of patients aged 18 years and older with a diagnosis of ESRD and receiving dialysis who received the influenza immunization during the flu season (September through February)
Influenza Vaccination in the ESRD Population - Facility Level	Percentage of all ESRD patients aged 18 years and older receiving hemodialysis and peritoneal dialysis during the flu season (October 1 - March 31) who receive an influenza vaccination during the October 1 - March 31 reporting period.
Patient Education, Perception of Care, and Quality of Life	Measure Description
Patient Education Awareness – Facility Level	Percentage of all ESRD patients 18 years and older with documentation regarding a discussion of renal replacement therapy modalities (including hemodialysis, peritoneal dialysis, home hemodialysis, transplants and identification of potential living donors, and no treatment). Measured once a year.
Patient Education Awareness – Clinician Level	Percentage of all ESRD patients 18 years and older with documentation regarding a discussion of renal replacement therapy modalities (including hemodialysis, peritoneal dialysis, home hemodialysis, transplants and identification of potential living donors, and no treatment). Measured once a year.
CAHPS In-Center Hemodialysis Survey – Facility Level	57 question survey that assesses patients' experience with In-Center Hemodialysis
Assessment of Health-related Quality of Life (Physical & Mental Functioning) – Facility Level	Percentage of dialysis patients who receive a quality of life assessment using the KDQOL-36 (36-question survey that assesses patients' functioning and well-being) at least once per year.
Patient Survival	Measure Description
Facility Patient Survival Classification (based of Standardized Mortality Ratio) – Facility Level	Risk-adjusted standardized mortality ratio for dialysis facility patients